Dual incretin receptor agonist
Tirzepatide
GIP / GLP-1 receptor agonist
FDA-approved formulations existA dual GIP and GLP-1 receptor agonist approved in specific branded formulations for type 2 diabetes and chronic weight management or obstructive sleep apnea in defined populations.
FULL RESEARCH GRAPHIC
Tirzepatide research overview
A dedicated overview of dual GIP and GLP-1 signaling and the distinction between approved formulations and the 30 mg research vial.
Tap the graphic to open the full-resolution version.
RESEARCH SIGNAL MAP
04 ACTIVE FIELDSEVIDENCE READOUT
FDA-approved formulations existRobust clinical evidence supports FDA-approved tirzepatide products, but that evidence does not establish equivalence of an independently compounded or research vial.
BOUNDARY CHECK
CONTEXT REQUIREDApproved tirzepatide is a finished prescription solution with controlled strength and instructions. A lyophilized third-party vial is not interchangeable with Zepbound or Mounjaro.
SUBMITTED LAB DOCUMENTS
Test results
Reports may describe other strengths or blends. Match the labeled amount, composition, and exact lot to your vial. A report for another strength does not verify your vial. Each record identifies whether an exact lot was supplied.
VIAL REFERENCE
3 mL mixing math & dosing context
Every number is labeled by evidence level. The 3 mL reference calculates concentration and U-100 volume; it does not prove solvent compatibility, sterility, stability, or suitability for injection.
FDA label: Zepbound
The FDA label starts adults at 2.5 mg once weekly for four weeks, then increases to 5 mg; later increases are 2.5 mg after at least four weeks at the current dose. Maintenance and maximum doses depend on indication and tolerability.
Approved products are supplied as solutions
Zepbound is supplied in ready-to-use pens or vials and is not reconstituted. Those instructions do not apply to an independently sourced lyophilized vial.